Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...

Under the temporary reign of top food executive Kyle Diamantas, the FDA will sustain programs initiated by former ...

From Eli Lilly's David Ricks to Pfizer's Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025 ...

Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major ...

Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual ...

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...